-
1
-
-
24144433366
-
-
R. Noll (Ed.), Challenges to Research Universities, 171-200, Washington, DC: The Brookings Institution
-
Cohen, W., Florida, R., Randasses, L. & Walsh, J. Industry and the academy: uneasy partners in the cause of technological advance. in R. Noll (Ed.), Challenges to Research Universities, 171-200, Washington, DC: The Brookings Institution (1998).
-
(1998)
Industry and the Academy: Uneasy Partners in the Cause of Technological Advance
-
-
Cohen, W.1
Florida, R.2
Randasses, L.3
Walsh, J.4
-
2
-
-
0001459704
-
Real effects of academic research
-
Jaffe, A. Real effects of academic research. Am. Econ. Rev. 79, 957-970 (1989).
-
(1989)
Am. Econ. Rev
, vol.79
, pp. 957-970
-
-
Jaffe, A.1
-
3
-
-
0002034724
-
Academic research and industrial innovation
-
Mansfield, E. Academic research and industrial innovation. Res. Policy 20, 1-12 (1991).
-
(1991)
Res. Policy
, vol.20
, pp. 1-12
-
-
Mansfield, E.1
-
4
-
-
84870343115
-
The economic impact of licensed commercialized inven-tions originating in university research
-
Roessner, D., Bond, J., Okubo, S. & Planting, M. The economic impact of licensed commercialized inven-tions originating in university research. Res. Policy 42, 23-34 (2013).
-
(2013)
Res. Policy
, vol.42
, pp. 23-34
-
-
Roessner, D.1
Bond, J.2
Okubo, S.3
Planting, M.4
-
5
-
-
30544437182
-
The licensing of DNA patents by US academic institutions: An empirical survey
-
Pressman, L. et al. The licensing of DNA patents by US academic institutions: an empirical survey. Nat. Biotechnol. 24, 31-39 (2006).
-
(2006)
Nat. Biotechnol
, vol.24
, pp. 31-39
-
-
Pressman, L.1
-
6
-
-
80051548581
-
30 years after Bayh-Dole: Reassessing academic entrepreneurship
-
Grimaldi, R., Kenney, M., Siegel, D.S. & Wright, M. 30 years after Bayh-Dole: reassessing academic entrepreneurship. Res. Policy 40, 1045-1057 (2011).
-
(2011)
Res. Policy
, vol.40
, pp. 1045-1057
-
-
Grimaldi, R.1
Kenney, M.2
Siegel, D.S.3
Wright, M.4
-
9
-
-
58149242549
-
Academic patents and access to medicines in developing countries
-
Sampat, B.N. Academic patents and access to medicines in developing countries. Am. J. Public Health 99, 9-17 (2009).
-
(2009)
Am. J. Public Health
, vol.99
, pp. 9-17
-
-
Sampat, B.N.1
-
10
-
-
76149092908
-
Private sector contributions to pharmaceutical science: Thirty-five summary case histories
-
Zycher, B., DiMasi, J.A. & Milne, C.-P. Private sector contributions to pharmaceutical science: thirty-five summary case histories. Am. J. Ther. 17, 101-120 (2010).
-
(2010)
Am. J. Ther
, vol.17
, pp. 101-120
-
-
Zycher, B.1
Dimasi, J.A.2
Milne, C.-P.3
-
11
-
-
78049467253
-
The importance of new companies for drug discovery: Origins of a decade of new drugs
-
Kneller, R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9, 867-882 (2010).
-
(2010)
Nat. Rev. Drug Discov
, vol.9
, pp. 867-882
-
-
Kneller, R.1
-
12
-
-
79955636638
-
What are the respective roles of the public and private sectors in pharmaceutical innovation?
-
Sampat, B.N. & Lichtenberg, F.R. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Aff. 30, 332-339 (2011).
-
(2011)
Health Aff
, vol.30
, pp. 332-339
-
-
Sampat, B.N.1
Lichtenberg, F.R.2
-
13
-
-
79851477450
-
The role of public sector research in the discovery of drugs and vaccines
-
Stevens, A.J., Jensen, J.J., Wyller, K., Chatterjee, S. & Rohrbaugh, M.L. The role of public sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364, 535-541 (2011).
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 535-541
-
-
Stevens, A.J.1
Jensen, J.J.2
Wyller, K.3
Chatterjee, S.4
Rohrbaugh, M.L.5
-
15
-
-
80053219051
-
An empirical review of major legislation affecting drug development: Past experiences, effects and unintended consequences
-
Kesselheim, A.S. An empirical review of major legislation affecting drug development: past experiences, effects and unintended consequences. Milbank Q. 89, 450-502 (2011).
-
(2011)
Milbank Q
, vol.89
, pp. 450-502
-
-
Kesselheim, A.S.1
-
16
-
-
25144518364
-
Financial anatomy of biomedical research
-
Moses, H. III, Dorsey, E.R., Matheson, D.H. & Their, S.O. Financial anatomy of biomedical research. J. Am. Med. Assoc. 294, 1333-1342 (2005).
-
(2005)
J. Am. Med. Assoc
, vol.294
, pp. 1333-1342
-
-
Moses Iii., H.1
Dorsey, E.R.2
Matheson, D.H.3
Their, S.O.4
-
18
-
-
84892188648
-
-
National Institutes of Health Office of Technology Transfer
-
National Institutes of Health Office of Technology Transfer. Fludara The New Benchmark: A Case Study. http://www.ott.nih.gov/sites/default/files/ documents/pdfs/FludaraCS.pdf (2003).
-
(2003)
Fludara the New Benchmark: A Case Study
-
-
-
19
-
-
73949089207
-
Financial anatomy of biomedical research 2003-2008
-
Dorsey, E.R. et al. Financial anatomy of biomedical research 2003-2008. J. Am. Med. Assoc. 303, 137-143 (2010).
-
(2010)
J. Am. Med. Assoc
, vol.303
, pp. 137-143
-
-
Dorsey, E.R.1
-
20
-
-
2942595810
-
Abbott defends Norvir price hike
-
Mullin, R. Abbott defends Norvir price hike. Chem. Eng. News 82, 6 (2004).
-
(2004)
Chem. Eng. News
, vol.82
, pp. 6
-
-
Mullin, R.1
-
21
-
-
79952587191
-
The cost of drug development: A systematic review
-
Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., Greyson, D. The cost of drug development: a systematic review. Health Policy. 100, 4-17(2010).
-
(2010)
Health Policy
, vol.100
, pp. 4-17
-
-
Morgan, S.1
Grootendorst, P.2
Lexchin, J.3
Cunningham, C.4
Greyson, D.5
-
23
-
-
84892162010
-
-
National Institutes of Health. Actual Obligations by Institute and Center, FY 2000-FY 2012
-
National Institutes of Health. Actual Obligations by Institute and Center, FY 2000-FY 2012 (2010).
-
(2010)
-
-
|